Completed PHASE2 INTERVENTIONAL 2-arm NCT05613842

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) (BOP)

Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer

Sponsor: Clarity Pharmaceuticals Ltd

Interventions Copper-64 labelled SAR-Bombesin

Updated 5 times since 2022 Last updated: Sep 24, 2023 Started: Aug 9, 2022 Primary completion: Jun 6, 2023 Completion: Jun 6, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05613842, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Clarity Pharmaceuticals Ltd, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clarity Pharmaceuticals Ltd
St Vincent's Hospital, Sydney

Data source: St Vincent's Hospital, Sydney

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia